Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty CompounderSeeking Alpha · 1 day ago
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)Defense World · 6 days ago
Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)Defense World · Oct 16, 2026
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research · Oct 15, 2026
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head ReviewDefense World · Sep 24, 2026
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in StockDefense World · Sep 13, 2026Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $2.23 | $2.29 | Beat |
| May 5, 2026 | -$0.65 | $0.05 | Beat |
| Feb 25, 2026 | -$0.53 | -$0.69 | Miss |
| Nov 6, 2025 | -$0.59 | -$0.62 | Miss |
| Aug 6, 2025 | -$0.53 | -$0.55 | Miss |
| May 6, 2025 | -$0.50 | -$0.19 | Beat |